PXD074216 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Molecular principles of CRISPR-Cas13b design for selective silencing of oncogenic fusion transcripts |
| Description | Oncogenic gene fusions are key drivers of cancer, yet most remain untargetable by current therapies. Here, we establish CRISPR-PspCas13b as a personalisable platform for systematic silencing of various fusion transcripts. We reveal that recognition and cleavage of the breakpoint sequence by PspCas13b disrupts the fusion transcript, resulting in efficient protein depletion. Short and long-read RNA sequencing reveal that PspCas13b cleavage produces aberrant, translation-incompetent RNA isoforms with internal deletions proximal to the cleavage site. Importantly, we demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both canonical and drug-resistant BCR::ABL1 mutants, which are the primary drivers of tyrosine kinase inhibitor (TKI) resistance and relapse in chronic myeloid leukemia (CML). Molecular profiling revealed that PspCas13b impairs BCR::ABL1 tyrosine phosphokinase activity and triggers extensive transcriptomic and proteomic remodelling, ultimately leading to erythroid differentiation and apoptosis in CML cells that are fully resistant to clinical drugs. Beyond BCR::ABL1 mutants, personalised design of PspCas13b effectively silences other undruggable fusions, including RUNX1::RUNX1T1 and EWSR1::FLI1, key drivers in acute myeloid leukemia and in Ewing’s sarcoma, respectively. Collectively, this study establishes a molecular framework for precise and personalizable targeting of otherwise undruggable or drug-resistant oncogenic transcripts. |
| HostingRepository | PRIDE |
| AnnounceDate | 2026-08-26 |
| AnnouncementXML | Submission_2026-08-25_21:48:39.091.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Wenxin Hu |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606; |
| ModificationList | iodoacetamide derivatized residue |
| Instrument | Orbitrap Fusion |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
| 0 | 2026-02-08 23:07:25 | ID requested | |
| ⏵ 1 | 2026-08-25 21:48:39 | announced | |
Publication List
| Dataset with its publication pending |
Keyword List
Contact List
| Mohamed Fareh |
| contact affiliation | Peter MacCallum Cancer Centre, Melbourne, 3000, Australia |
| contact email | mohamed.fareh@petermac.org |
| lab head | |
| Wenxin Hu |
| contact affiliation | 1Peter MacCallum Cancer Centre, Melbourne, 3000, Australia
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3052, Australia |
| contact email | wenxin.hu@petermac.org |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/08/PXD074216 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD074216
- Label: PRIDE project
- Name: Molecular principles of CRISPR-Cas13b design for selective silencing of oncogenic fusion transcripts